You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Transcatheter Aortic Valve IMPLANTATION (TAVI)
The Medtronic Evolut™ platform is designed for valve durability, because the best reintervention is the one that never needs to happen.
With its supra-annular, self-expanding valve frame, Evolut™ TAVI is built on the original CoreValve™ platform which, has consistently shown strong EOAs and low gradients over time.
How did we design for durability?
By decoupling the native annular plane where the sealing occurs, from the working portion of the prosthetic leaflets, you can facilitate circularity and maximize leaflet coaptation.
Taller leaflet mounting allows for a greater distance between the commissure and the edge of the leaflet, distributing stress over a greater distance.
The tall valve keeps the working portion above and unconstrained by the native annulus (supra-annular), allowing for a large effective orifice area (EOA).
Large EOAs mean less restriction of blood through the valve.
Less restriction leads to low gradients (mean systolic gradient).
Large EOAs have been correlated to less patient-prosthesis mismatch (PPM).
Less PPM and low gradients after aortic valve implantation have been linked to:
CoreValve™ and Evolut™ TAVI systems are the only platform to demonstrate a durability benefit over SAVR at five years.*6
* In pooled analysis of intermediate and high-risk patients. Devices used: CoreValve 88.5%/Evolut R 11.5%.
† Structural valve deterioration (SVD) was defined as an increase in mean gradient ≥ 10 mm Hg over five years with a mean gradient ≥ 20 mm Hg at last echo OR new onset/increase of central AR of ≥ moderate in severity.
TAVI risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.
Playford D, Stewart S, Celermajer D, et al. Poor Survival with Impaired Valvular Hemodynamics After Aortic Valve Replacement: The National Echo Database Australia Study. J Am Soc Echocardiogr. 2020;33(9):1077–1086.e1.
Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. J Am Coll Cardiol. 2018;72(22):2701–2711.
Anand V, Ali MA, Naser J, et al. Incidence, Mechanisms, and Predictors of Mean Systolic Gradients ≥20 mm Hg after Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020;125(6):941–947.
O’Hair D. Presented at American College of Cardiology 70th Annual Scientific Session & Expo. May 2021.
Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. J Am Coll Cardiol. 2019;73(5):546–553.
Reardon M. 5-Year Incidence, Timing and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials. Presented at ACC 2022. Updated data on file.